Compare SND & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SND | TNYA |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | 318 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.2M | 171.4M |
| IPO Year | 2016 | 2021 |
| Metric | SND | TNYA |
|---|---|---|
| Price | $5.45 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 298.1K | ★ 4.8M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $330,153,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.03 | N/A |
| 52 Week Low | $1.76 | $0.53 |
| 52 Week High | $5.84 | $2.35 |
| Indicator | SND | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 40.54 |
| Support Level | $3.56 | $0.65 |
| Resistance Level | $5.69 | $0.82 |
| Average True Range (ATR) | 0.32 | 0.07 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 74.18 | 3.07 |
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics. The company has two reportable segments, Sand and SmartSystems. It derives maximum revenue from Sand segment, which includes both frac sand sales and IPS sales. Geographically, the company derives maximum revenue from United States, followed by Canada.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.